Clinical trials: G-CSF, open to volunteers
Soft-tissue Sarcoma, Triple Negative Breast Cancer
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small…
- Conditions
- Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT07064018
- Testing
- Spedox-6, Pegfilgrastim, Filgrastim
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, Irvine
Pediatric Hematologic Malignancies
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft…
- Trial name
- NCT05011422
- Testing
- Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia
MRD Response-adapted Allo-HSCT for Adverse-risk AML
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
- Trial name
- NCT06301425
- Testing
- Intervention group, Control group
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, First Line Therapy
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid…
- Trial name
- NCT06928376
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese PLA General Hospital
Chronic Granulomatous Disease X-linked (X-CGD)
Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD
This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.
- Trial name
- XCGD-MOBI (NCT03055247)
- Testing
- Ibuprofen, Myelostim, Mozobil
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- IRCCS San Raffaele
Sickle Cell Disease
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can…
- Trial name
- SUN (NCT03587272)
- Testing
- Alemtuzumab, low dose total body irradiation, Sirolimus
- Where
- 7 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Robert Nickel
Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT07216703
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab
- Where
- 182 sites in United States, Argentina and 26 more
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Sepsis
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments.
- Trial name
- PALETTE (NCT06381661)
- Testing
- Tocilizumab, Baricitinib, Anakinra
- Where
- 19 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer of Stomach, Adenocarcinoma
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
This is a single centre randomised controlled trial, comparing perioperative FLOT versus adjuvant XELOX for locally advanced gastric and esophagogastric junction cancers.
- Trial name
- NCT05264896
- Testing
- 5-FU, Leucovorin, Oxaliplatin, Docetaxel, XELOX
- Where
- Hong Kong
- Volunteers
- 110 people
- Sponsor
- Chinese University of Hong Kong
Hematopoietic and Lymphoid System Neoplasm
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of bendamustine when given with or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients undergoing stem cell transplant.
- Trial name
- NCT04022239
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
This is a prospective, randomized, controlled clinical study designed to evaluate the efficacy and safety of Romiplostim N01 in promoting platelet engraftment after haploidentical allogeneic hematopoietic stem cell…
- Conditions
- Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment, HSCT
- Trial name
- NCT07321626
- Testing
- Romiplostim N01, Standard Supportive Care
- Where
- China
- Volunteers
- 130 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Severe Aplastic Anemia
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
- Trial name
- BMT CTN CureAA (NCT06517641)
- Testing
- Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
- Where
- 25 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medical College of Wisconsin
Diamond Blackfan Anemia
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)
Gene therapy is a new possible treatment for the anemia of DBAS. Gene therapy will soon be available for patients with RPS19-mutated DBAS.
- Trial name
- NCT07186179
- Testing
- Mobilization Regimen
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers.
- Trial name
- NCT05436418
- Testing
- Melphalan, Sirolimus, Total Body Irradiation (TBI)
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Background: Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemia.
- Trial name
- NCT01174108
- Testing
- Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Plasma Cell Leukemia
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell…
- Trial name
- NCT07605416
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 11 sites in United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Diffuse Large B-cell Lymphoma
A Phase I/II Study of Diffuse Large B-cell Lymphoma
For continuous variables, mean, median, minimum, and maximum will be used for the descriptive purpose. For categorical variables, frequency and percentage will be used for descriptive statistics.
- Trial name
- DLBL (NCT04856137)
- Testing
- Rituximab Paclitaxel Ruxolitinib
- Volunteers
- 74 people
- Sponsor
- National Health Research Institutes, Taiwan
Aplastic Anemia
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Outcomes for adult patients with Severe Aplastic Anemia (SAA) aged more than 40 years who are refractory or in relapse after first-line IST remain poor.
- Trial name
- APARR (NCT06646497)
- Testing
- Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow
- Where
- 26 sites in France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
Autologous hematopoietic stem cell transplantation(auto-HSCT) plays an important role in treating hematologic malignancies. Mobilization and collection of peripheral blood stem/progenitor cells is the key to successful autologous…
- Conditions
- Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients
- Trial name
- NCT07362810
- Testing
- G-CSF+IL-11, G-CSF Granulocyte-Colony Stimulating Factor
- Where
- 7 sites in China
- Volunteers
- 224 people
- Sponsor
- Fudan University